Securities code: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) securities abbreviation: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) Announcement No.: 2022037 Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266)
Plan for issuing A-Shares to specific objects in 2021
(Revised Version) suggestive announcement of disclosure
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) (hereinafter referred to as “the company”) held the first meeting of the second board of directors and the first meeting of the second board of supervisors on May 19, 2022, The proposal on the company’s plan to issue A-Shares to specific objects in 2021 (Revised Draft), the proposal on the company’s plan to issue A-Shares to specific objects in 2021 (Revised Draft), the proposal on the demonstration and analysis report of the company’s plan to issue A-Shares to specific objects in 2021 (Revised Draft) and other relevant proposals were reviewed and passed, It also revised the company’s plan to issue A-Shares to specific objects in 2021.
Relevant documents such as Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) 2021 plan for issuing A-Shares to specific objects (Revised Version), Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) 2021 demonstration and analysis report for issuing A-Shares to specific objects (Revised Version) have been posted on the website of Shanghai Stock Exchange (www.sse. Com. CN) Disclosure, please pay attention to the majority of investors.
The matters stated in the revised company’s 2021 plan for issuing A-Shares to specific objects do not represent the substantive judgment, confirmation, approval or approval of the audit authority on matters related to the issuance of A-Shares to specific objects. The effectiveness and completion of the matters related to the issuance of A-Shares to specific objects mentioned in the plan need to be reviewed and approved by Shanghai Stock Exchange, It can be implemented only after the China Securities Regulatory Commission makes a decision on approval and registration. Please pay attention to the risks.
It is hereby announced.
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) May 20, 2022
